Table 3:

Treatment-emergent adverse events (safety set)

	Any grade	Grade 3	Grade 4	Grade 5
Any treatment-emergent adverse event	117 (100%)	18 (15%)	85 (73%)	5 (4%)*
Cytokine release syndrome	99 (85%)	10 (9%)	0	0
Anaemia	78 (67%)	61 (52%)	0	0
Neutropenia	72 (62%)	11 (9%)	60 (51%)	0
Thrombocytopenia	58 (50%)	14 (12%)	34 (29%)	0
Fatigue	40 (34%)	7 (6%)	0	0
Nausea	39 (33%)	0	0	0
Diarrhoea	34 (29%)	1 (1%)	0	0
Headache	34 (29%)	1 (1%)	0	0
Leukopenia	34 (29%)	3 (3%)	28 (24%)	0
Hypokalaemia	32 (27%)	2 (2%)	0	0
Pyrexia	32 (27%)	1 (1%)	0	0
Confusional state	31 (26%)	11 (9%)	0	0
Hypocalcaemia	30 (26%)	5 (4%)	0	0
Constipation	29 (25%)	0	0	0
Decreased appetite	29 (25%)	4 (3%)	0	0
Dizziness	29 (25%)	0	0	0
Hypophosphataemia	28 (24%)	14 (12%)	2 (2%)	0
Tremor	28 (24%)	2 (2%)	0	0
Lymphopenia	24 (21%)	7 (6%)	16 (14%)	0
Hypomagnesaemia	24 (21%)	0	0	0
Decreased blood fibrinogen	23 (20%)	6 (5%)	0	0
Hyperglycaemia	23 (20%)	10 (9%)	2 (2%)	0

Data are n (%). The table includes the most common treatment-emergent adverse events (≥20%) in the full population (n=117). Liso-cel=lisocabtagene maraleucel.

^*Four of the five deaths from adverse events were considered by investigators to be unrelated to liso-cel (respiratory failure, sepsis, Escherichia coli infection, and invasive aspergillosis; n=1 each) and one death was related to liso-cel (macrophage activation syndrome-haemophagocytic lymphohistiocytosis)